Clinuvel Pharmaceuticals (ASX:CUV, ADR:CLVLY) could significantly improve the quality of life for patients with a genetic disorder that causes severe skin burns from exposure to light.
Combined analyses of pivotal Phase III studies of its SCENESSE® treatment show an increase in the duration of patient sun exposure without phototoxicity.
The findings were published in the New England Journal of Medicine, which has the highest impact factor of all medical periodicals.
The pivotal studies also led to the December 2014 European marketing authorisation .
SCENESSE® treats erythropoietic protoporphyria (EPP), a complex orphan genetic disorder where severe dermal burns can result from any exposure to light, resulting in prolonged distress and incapacitation.
Patients experience intense fear of incurring phototoxicity due to light exposure.
As previously reported by Clinuvel, the majority of patients who received SCENESSE® have expressed that the drug provided them a freedom to lead a life they had not had before, enabling them to participate in outdoor activities without fear of severe incapacitating symptoms.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.